Alnylam
Listed as Alnylam Pharmaceuticals
Forbes Global 2000 2002 #1587 by revenue United States Healthcare Drugs & Biotechnology alnylam.com
Alnylam Pharmaceuticals, Inc.
Forbes Global 2000's description, shown to identify the company. We rate the name, not the business.
- Evocativity EVOC : red
- No recognizable pharmaceutical root
- Brevity BREV : green
- 7 letters, 3 syllables. Up to seven letters is green, eight at two syllables too; up to ten yellow, eleven or more red.
- Greppability GREP : green
- Found inside 0 other dictionary words.
- Googlability GOOG : green
- Distinctive coined word
- Pronounceability PRON : red
- Unfamiliar consonant and vowel sequence
- Spellability SPEL : red
- Syllables cannot be reconstructed reliably
- Verbability VERB : red
- No natural treatment use verb
- Nominology
- 50
- All seven dimensions and .com ownership, weighted as set out on Methodology.
- Fluency
- 40
- Brevity and pronounceability only: the subset with published outcome evidence behind it.
- PG grade
- 3 / 4
- Graham's own four-step ladder.
- Exact .com
- Owned
- Shape
- invented
- Length
- 7 chars, 3 syllables
- Distinctiveness
- fanciful
Watkins SCRATCH flags
- Spelling-challenged
- Hard-to-pronounce
This row is stitched from more than one source. Forbes Global 2000 supplied the company; site+wikidata+domain filled brand_name.
Rubric version 2026.10.20-1, judged by gpt-6.1-sol (agent).
This scores the name only. See Methodology.
These judged dimensions came from an AI agent working through the judging queue in a chat, on the same rubric the scoring pipeline sends. The agent passed the calibration exam before its work was accepted, and each batch it judged hid two names with known answers as a check. The model is named as the agent reported it.